Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Vericel Corporation
VCEL
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.3B
$46.22
▲ +2.38%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$28.95 - $46.62
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 8.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary autologous cell therapy technology with established manufacturing capabilities
- FDA-approved products with established market presence and reimbursement pathways
- Orphan drug designation and humanitarian use device status providing regulatory advantages
- Specialized expertise in cellular therapy commercialization and clinical application
Bear Case
2 risks
- Average volatility.
- Growth premium of 3.3x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Growth
Moderate growth ahead
Expanding MACI adoption in orthopedic surgery and sports medicine markets
Value
Growth premium of 3.3x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Momentum
Hot
+32.3% over 3m
Quality
Excellent
High-growth business (23% revenue growth, 75% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying VCEL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of -$0.12 vs -$0.15 consensus (+20.0% surprise). Revenue of $68.4M vs $63.7M expected (+7.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+20.0%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+16%
+3%
+20%
+17%
+23%
+30%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$52.7M
$57.9M
$75.4M
$52.6M
$63.2M
$67.5M
$92.9M
$68.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
-9.2%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$56.00
▲ +21.1% vs $46.22
Latest: HC Wainwright · $70.00 · May 8, 2026
2 analysts covering